moxaverine moxaverine moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor, and on its influence on the rheological properties of red blood cells. moxaverineclinical dataahfs/drugs.cominternational drug namesatc codea03ad30 (who) identifiers iupac name 1-benzyl-3-ethyl-6,7-dimethoxyisoquinoline cas number10539-19-2 ypubchem cid70882chemspider64045 nuniip3p08y1xj4keggd07089 ycomptox dashboard (epa)dtxsid6057613 echa infocard100.031.003 chemical and physical dataformulac20h21no2molar mass307.393 g·mol−13d model (jsmol)interactive image smiles ccc1=nc(=c2c=c(c(=cc2=c1)oc)oc)cc3=cc=cc=c3 inchi inchi=1s/c20h21no2/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14/h5-9,11-13h,4,10h2,1-3h3 nkey:mycmtmigrxjnso-uhfffaoysa-n n ny (what is this?) (verify) moxaverine hydrochloride (kollateral forte®, ursapharm. saarbrücken, germany) has been shown to increase ocular blood flow in patients with age-related macular degeneration, primary open angle glaucoma, and to increase choroidal and retrobulbar blood flow in elderly patients with eye diseases associated with hypo-perfusion. the ocular efficacy of moxaverine has been explored in the clinic.